Phase 1 trial of Talaporfin (Laserphyrin / NPe6) in neurofibromatosis treats first patient

Not a full case report or a medical first but it is the first patient in a phase 1 trial of this intriguing, light-activated chemotherapy drug in children with plexiform neurofibromas.

“Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated drug Aptocine™ (talaporfin sodium) in neurofibromatosis type 1 (NF-1). Investigators at the Neurofibromatosis/Neuro-Oncology Clinic of Children’s Hospital of Philadelphia (CHOP) treated a pediatric patient with NF-1 and plexiform neurofibromas (PN) using Aptocine, which is also in late-stage development for solid tumors. The Neurofibromatosis/Neuro- Oncology Clinic is a program providing care and treatment for children with brain tumors and children with NF-1 and severe and/or life-threatening tumors.”